FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/VRTX
icon
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Vertex Pharmaceuticals (VRTX) trades at $542.5, down 1.19% on the day, with a bullish technical setup supported by moving averages and positive ADX signals. The company reported $12.0B revenue for 2025, with a net income of $3.95B and strong profitability margins, though recent quarterly EPS results have been mixed with three misses out of four quarters. Positive Phase II data for its kidney disease drug inaxaplin and dominant cystic fibrosis market position underpin growth prospects.
The outlook remains positive given analyst consensus with a $580.20 price target and 85.71% buy ratings, but risks include execution on pipeline candidates, competitive pressures, and reliance on cystic fibrosis treatments. Net cash flow turned positive in 2025 at $515.60M after a significant outflow in 2024, indicating improved financial health.
Read full analysis

Key Stats

  • Market Cap
    $137.54B
  • Volume
    2,467,517
  • Sector
    Health
  • 52W High
    $559.41
  • 52W Low
    $409.47
  • Typical Hold Time
    123 Days
  • Enterprise Value
    $137.72B
  • Div Yield
    -
  • Trading Activity
    92% Sell | 8% Buy
$547.09
52W Low: $409.47
07 Nov 2025
52W High: $559.41
30 Oct 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $409.47 and a high of $559.41, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Most Recent News

Content is generated by Aura AI

BNP Paribas shares dip on French unrest fears but remain a buy due to strong fundamentals.

Shares of BNP Paribas have fallen about 10% amid concerns over French political unrest potentially impacting earnings and capital. However, the bank's French retail banking is a minor income source and benefits from structural strengths that can offs...

Market News
5 hours ago
Seeking Alpha
Bullish
news icon
BNP Paribas shares dip on French unrest fears but remain a buy due to strong fundamentals.

WPP remains a 'buy' with improving Q3 results and attractive valuation despite AI sector challenges

WPP is recommended as a 'buy' due to its attractive valuation amid skepticism about AI's impact on the sector. The company’s Q3 results showed a 0.5% revenue increase, disciplined cost management, and a £0.6bn reduction in net debt year-on-year. Whil...

Market News
5 hours ago
Seeking Alpha
Bullish
news icon
WPP remains a 'buy' with improving Q3 results and attractive valuation despite AI sector challenges

Berkshire Hathaway rises 5% amid worst stock week since April 2025, holding $365B cash for buying opportunities.

During the worst stock market week since April 2025, Warren Buffett's Berkshire Hathaway shares rose 5.2%, reaching a record high while holding about $365 billion in cash. This cash reserve, about 29% of Berkshire's market value, allows the company t...

Market News
6 hours ago
24/7 Wall Street
Bullish
news icon
Berkshire Hathaway rises 5% amid worst stock week since April 2025, holding $365B cash for buying opportunities.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $137.54B
  • Volume
    2,467,517
  • Sector
    Health
  • 52W High
    $559.41
  • 52W Low
    $409.47
  • Typical Hold Time
    123 Days
  • Enterprise Value
    $137.72B
  • Div Yield
    -
  • Trading Activity
    92% Sell | 8% Buy
$547.09
52W Low: $409.47
07 Nov 2025
52W High: $559.41
30 Oct 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $409.47 and a high of $559.41, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!